FluBlok®

FluBlok® is Protein Sciences' seasonal influenza vaccine candidate.

The company has conducted Phase III clinical studies for FluBlok. At this time a Biologics License Application (BLA) for commercialization of FluBlok is under review at the FDA.

FluBlok is comprised of purified recombinant hemagglutinin antigens (active ingredient) and is formulated to contain 3X the active component as compared to TIV.

Over 90% of influenza-related deaths occur in people over the age of 65. Currently available vaccines have a limited ability to protect the elderly, the age group most at risk for influenza. Clinical trials to date demonstrated that a significantly higher percentage of elderly subjects who received FluBlok developed antibody titers considered to be protective compared to subjects who received the licensed vaccine.

FluBlok Advantages:

Higher antigen content
Better immunogenicity for the elderly
No adjuvants and no preservatives (i.e. no thimerisol)
No egg proteins present
No live influenza viruses used in production